A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
This is a clinical study to compare noninvasive hypoxia imaging using 18F-fluoroerythronitroimidazole (18F-FETNIM) and 18F-fluoromisonidazole (18F-FMISO) positron emission tomography/computed tomography (PET/CT) in patients with inoperable stages III-IV lung cancer.A total of forty-two patients with...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4913930?pdf=render |
id |
doaj-3e2ae22e67a34ca08f623c886e680fa9 |
---|---|
record_format |
Article |
spelling |
doaj-3e2ae22e67a34ca08f623c886e680fa92020-11-24T22:11:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01116e015760610.1371/journal.pone.0157606A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.Yuchun WeiWei ZhaoYong HuangQingxi YuShouhui ZhuSuzhen WangShuqiang ZhaoXudong HuJinming YuShuanghu YuanThis is a clinical study to compare noninvasive hypoxia imaging using 18F-fluoroerythronitroimidazole (18F-FETNIM) and 18F-fluoromisonidazole (18F-FMISO) positron emission tomography/computed tomography (PET/CT) in patients with inoperable stages III-IV lung cancer.A total of forty-two patients with inoperable stages III-IV lung cancer underwent 18F-FETNIM PET/CT (n = 18) and 18F-FMISO PET/CT (n = 24) before chemo/radiation therapy. The standard uptake values (SUVs) of malignant and normal tissues depict 18F-FETNIM PET/CT and 18F-FMISO PET/CT uptake. Tumor-to-blood ratios (T/B) were used to quantify hypoxia.All patients with lung cancer underwent 18F-FETNIM PET/CT and 18F-FMISO PET/CT successfully. Compared to 18F-FMISO, 18F-FETNIM showed similar uptake in muscle, thyroid, spleen, pancreas, heart, lung and different uptake in blood, liver, and kidney. Significantly higher SUV and T/B ratio with 18F-FMISO (2.56±0.77, 1.98±0.54), as compared to 18F-FETNIM (2.12±0.56, 1.42±0.33) were seen in tumor, P = 0.022, <0.001. For the patients with different histopathological subtypes, no significant difference of SUV (or T/B ratio) was observed both in 18F-FMISO and 18F-FETNIM in tumor. A significantly different SUV (or T/B ratio) was detected between < = 2cm, 2~5cm, and >5cm groups in 18F-FMISO PET/CT, P = 0.015 (or P = 0.029), whereas no difference was detected in 18F-FMISO PET/CT, P = 0.446 (or P = 0.707). Both 18F-FETNIM and 18F-FMISO showed significantly higher SUVs (or T/B ratios) in stage IV than stage III, P = 0.021, 0.013 (or P = 0.032, 0.02).18F-FMISO showed significantly higher uptake than 18F-FETNIM in tumor/non-tumor ratio and might be a better hypoxia tracer in lung cancer.http://europepmc.org/articles/PMC4913930?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yuchun Wei Wei Zhao Yong Huang Qingxi Yu Shouhui Zhu Suzhen Wang Shuqiang Zhao Xudong Hu Jinming Yu Shuanghu Yuan |
spellingShingle |
Yuchun Wei Wei Zhao Yong Huang Qingxi Yu Shouhui Zhu Suzhen Wang Shuqiang Zhao Xudong Hu Jinming Yu Shuanghu Yuan A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. PLoS ONE |
author_facet |
Yuchun Wei Wei Zhao Yong Huang Qingxi Yu Shouhui Zhu Suzhen Wang Shuqiang Zhao Xudong Hu Jinming Yu Shuanghu Yuan |
author_sort |
Yuchun Wei |
title |
A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. |
title_short |
A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. |
title_full |
A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. |
title_fullStr |
A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. |
title_full_unstemmed |
A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. |
title_sort |
comparative study of noninvasive hypoxia imaging with 18f-fluoroerythronitroimidazole and 18f-fluoromisonidazole pet/ct in patients with lung cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
This is a clinical study to compare noninvasive hypoxia imaging using 18F-fluoroerythronitroimidazole (18F-FETNIM) and 18F-fluoromisonidazole (18F-FMISO) positron emission tomography/computed tomography (PET/CT) in patients with inoperable stages III-IV lung cancer.A total of forty-two patients with inoperable stages III-IV lung cancer underwent 18F-FETNIM PET/CT (n = 18) and 18F-FMISO PET/CT (n = 24) before chemo/radiation therapy. The standard uptake values (SUVs) of malignant and normal tissues depict 18F-FETNIM PET/CT and 18F-FMISO PET/CT uptake. Tumor-to-blood ratios (T/B) were used to quantify hypoxia.All patients with lung cancer underwent 18F-FETNIM PET/CT and 18F-FMISO PET/CT successfully. Compared to 18F-FMISO, 18F-FETNIM showed similar uptake in muscle, thyroid, spleen, pancreas, heart, lung and different uptake in blood, liver, and kidney. Significantly higher SUV and T/B ratio with 18F-FMISO (2.56±0.77, 1.98±0.54), as compared to 18F-FETNIM (2.12±0.56, 1.42±0.33) were seen in tumor, P = 0.022, <0.001. For the patients with different histopathological subtypes, no significant difference of SUV (or T/B ratio) was observed both in 18F-FMISO and 18F-FETNIM in tumor. A significantly different SUV (or T/B ratio) was detected between < = 2cm, 2~5cm, and >5cm groups in 18F-FMISO PET/CT, P = 0.015 (or P = 0.029), whereas no difference was detected in 18F-FMISO PET/CT, P = 0.446 (or P = 0.707). Both 18F-FETNIM and 18F-FMISO showed significantly higher SUVs (or T/B ratios) in stage IV than stage III, P = 0.021, 0.013 (or P = 0.032, 0.02).18F-FMISO showed significantly higher uptake than 18F-FETNIM in tumor/non-tumor ratio and might be a better hypoxia tracer in lung cancer. |
url |
http://europepmc.org/articles/PMC4913930?pdf=render |
work_keys_str_mv |
AT yuchunwei acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT weizhao acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT yonghuang acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT qingxiyu acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT shouhuizhu acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT suzhenwang acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT shuqiangzhao acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT xudonghu acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT jinmingyu acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT shuanghuyuan acomparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT yuchunwei comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT weizhao comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT yonghuang comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT qingxiyu comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT shouhuizhu comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT suzhenwang comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT shuqiangzhao comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT xudonghu comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT jinmingyu comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer AT shuanghuyuan comparativestudyofnoninvasivehypoxiaimagingwith18ffluoroerythronitroimidazoleand18ffluoromisonidazolepetctinpatientswithlungcancer |
_version_ |
1725804751360098304 |